Literature DB >> 10408704

Deletions of the region 17p11-13 in advanced melanoma revealed by cytogenetic analysis and fluorescence in situ hybridization.

I Okamoto1, H Pirc-Danoewinata, J Ackermann, J Drach, H Schlagbauer Wadl, B Jansen, K Wolff, H Pehamberger, C Marosi.   

Abstract

The significance of the p53 tumour-suppressor gene in the oncogenesis of a variety of malignant tumours has been demonstrated over recent years. However, the role of p53 in human malignant melanoma is still unclear. Therefore, we investigated melanoma metastases from 11 patients cytogenetically and with fluorescence in situ hybridization (FISH) after short-term culture, employing a p53 region-specific probe for 17p13.1 and a probe detecting the centromere of chromosome 17. Furthermore, paraffin-embedded tissue samples from nine of these patients were investigated immunohistochemically for expression of the p53 protein. Deletions of the short arm of chromosome 17 were seen in six melanomas in cytogenetic analysis. With FISH, three malignant melanomas had clones with only one p53-allele and an additional four malignant melanomas showed a reduced number of signals at the p53 tumour-suppressor gene locus compared with signals for the centromeric region of chromosome 17. This was confirmed by immunohistochemistry. Our results suggest that the 17p11-13 region is frequently deleted in malignant melanomas and that p53 or other genes located on this band might contribute to the malignant potential of advanced melanoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10408704      PMCID: PMC2362169          DOI: 10.1038/sj.bjc.6690022

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  32 in total

1.  Expression of p53 protein in cutaneous melanoma.

Authors:  L A Akslen; O Mørkve
Journal:  Int J Cancer       Date:  1992-08-19       Impact factor: 7.396

2.  Stable chromosome changes in human malignant melanoma.

Authors:  T R Chen; M W Shaw
Journal:  Cancer Res       Date:  1973-09       Impact factor: 12.701

3.  Immunohistochemical expression of p53 protein, mitotic index and nuclear morphometry in primary malignant melanoma of the skin.

Authors:  L Talve; J Kainu; Y Collan; T Ekfors
Journal:  Pathol Res Pract       Date:  1996-08       Impact factor: 3.250

4.  Expression of mutant p53 in melanoma.

Authors:  J R Stretch; K C Gatter; E Ralfkiaer; D P Lane; A L Harris
Journal:  Cancer Res       Date:  1991-11-01       Impact factor: 12.701

5.  Multiple karyotypic abnormalities, including structural rearrangements of 11p, in cell lines from malignant melanomas.

Authors:  S Heim; N Mandahl; K Arheden; B C Giovanella; S O Yim; J S Stehlin; F Mitelman
Journal:  Cancer Genet Cytogenet       Date:  1988-10-01

6.  Relation of cytogenetic abnormalities and clinical outcome in metastatic melanoma.

Authors:  J M Trent; F L Meyskens; S E Salmon; K Ryschon; S P Leong; J R Davis; D L McGee
Journal:  N Engl J Med       Date:  1990-05-24       Impact factor: 91.245

7.  Nonrandom chromosome structural aberrations and oncogene loci in human malignant melanoma.

Authors:  M I Pedersen; J W Bennett; N Wang
Journal:  Cancer Genet Cytogenet       Date:  1986-02-01

8.  Wild-type p53 is a cell cycle checkpoint determinant following irradiation.

Authors:  S J Kuerbitz; B S Plunkett; W V Walsh; M B Kastan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

9.  p53 mutations in human malignant gliomas: comparison of loss of heterozygosity with mutation frequency.

Authors:  R H Frankel; W Bayona; M Koslow; E W Newcomb
Journal:  Cancer Res       Date:  1992-03-15       Impact factor: 12.701

10.  Infrequent p53 gene mutations in medulloblastomas.

Authors:  R L Saylors; D Sidransky; H S Friedman; S H Bigner; D D Bigner; B Vogelstein; G M Brodeur
Journal:  Cancer Res       Date:  1991-09-01       Impact factor: 12.701

View more
  1 in total

1.  Longitudinal study of recurrent metastatic melanoma cell lines underscores the individuality of cancer biology.

Authors:  Zoltan Pos; Tara L Spivey; Hui Liu; Michele Sommariva; Jinguo Chen; John R Wunderlich; Giulia Parisi; Sara Tomei; Ben D Ayotte; David F Stroncek; Joel A Malek; Paul F Robbins; Licia Rivoltini; Michele Maio; Lotfi Chouchane; Ena Wang; Francesco M Marincola
Journal:  J Invest Dermatol       Date:  2013-11-22       Impact factor: 8.551

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.